Sputnik V close to public launch: Moscow will begin mass vaccination against Covid-19 at end of December, says Mayor Sobyanin
Sobyanin, who has run Europe's largest city since 2010, believes that mass vaccination will be “the final victory over the pandemic.”
Writing on his blog, the mayor explained that the high number of infections in Moscow is due to the city's huge population and the significant number of tests being conducted. On Monday, confirmed cases in the capital hit 367,629, a quarter of the country's overall number (1,415,316), despite officially having around only eight percent of the population.Also on rt.com WHO notes ‘alarming increase’ in Russian Covid-19 cases as the country once again breaks its daily record of confirmed infections
In the same blog post, Sobyanin highlighted that he does not yet see a necessity to introduce “extreme” measures in the city, such as a curfew and a ban on movement, but did not rule out other less stringent measures. The main aim is to interrupt the spread of the infection, while not affecting the economy or depriving people of work, he wrote.
“Ultimately, we are not making a choice between good and bad,” the mayor said. “All decisions are bad. We have to choose the lesser of two evils. But if we do nothing today, then tomorrow we will have to take tougher, more radical, and more unpleasant measures.”
Last week, the capital introduced extra restrictions regarding nightlife, with those attending bars and clubs after midnight being forced to scan a QR code for the purpose of track-and-trace.
Moscow is currently hosting the third phase trial of the country's homegrown Covid-19 vaccine, called Sputnik V. The mass post-registration testing of the vaccine, which was produced by the city's Gamaleya Institute, involves 40,000 volunteers – a quarter of whom will receive a placebo.Also on rt.com 'Sputnik V' worthy of Nobel Prize? Two Russian MPs think developers of world’s first Covid-19 vaccine should be recognised in 2021
On October 14, Russian President Vladimir Putin announced the registration of the second domestic vaccine, EpiVacCorona, developed in Siberia. A third formula is also said to be on the way.
Like this story? Share it with a friend!